title: Penetration of netilmicin in the lower respiratory tract after once-daily dosing.
abstract: A major criticism of the use of aminoglycosides for the treatment of pneumonia is the poor penetration in infected airways. Once-daily dosing of aminoglycosides results in higher peak plasma concentrations without increasing toxic reactions and with optimization of pharmacodynamic properties. To predict intrapulmonary antimicrobial activity after once-daily dosing of aminoglycosides, it is necessary to determine the respective bronchial and alveolar disposition. We prospectively conducted a pharmacokinetic study of netilmicin following the first intravenous administration of a once-daily dosing schedule in 20 ventilated patients with pneumonia. A bronchoscopic sampling of bronchial secretions and a subsegmental bronchoalveolar lavage (BAL) were performed 60, 90, 120, and 180 min (five patients at each time point) on the first treatment day after intravenous administration over 30 min of 450 mg of netilmicin. The netilmicin concentrations in the alveolar lining fluid (ALF) were calculated using urea as an endogenous marker of dilution. In bronchial secretions, a peak concentration of 2.00 (SEM: 0.26) mg/L or 6 percent of the 30-min plasma concentration was reached at 120 min. In ALF, much higher levels were found. At 120 min, a peak ALF concentration of 14.7 (SEM: 2.22) mg/L or 41 percent of the 30-min plasma concentration was reached. Spearman's rank correlation testing failed to show a correlation between bronchial and ALF concentrations. Higher plasma concentrations of netilmicin after once-daily dosing give rise to ALF concentrations exceeding the minimum inhibitory concentration of susceptible respiratory pathogens involved in nosocomial pneumonia, while bronchial concentrations remain low. Aminoglycoside concentrations in bronchial secretions cannot be used to predict alveolar concentrations. Low diffusibility can no longer be considered as a disadvantage of aminoglycosides for treating pneumonias.
authors.affiliation: Department of Respiratory Diseases, University Hospital, Ghent, Belgium.
authors.forename: Y J
authors.initials: YJ
authors.lastname: Valcke
authors.forename: D P
authors.initials: DP
authors.lastname: Vogelaers
authors.forename: F A
authors.initials: FA
authors.lastname: Colardyn
authors.forename: R A
authors.initials: RA
authors.lastname: Pauwels
mesh_terms: D000328:Adult; D000368:Aged; D000900:Anti-Bacterial Agents / Q000627:therapeutic use; D001992:Bronchoalveolar Lavage Fluid / Q000737:chemistry; D001999:Bronchoscopy; D004359:Drug Therapy, Combination; D006207:Half-Life; D006801:Humans; D007769:Lactams; D008875:Middle Aged; D009428:Netilmicin / Q000008:administration & dosage / Q000032:analysis / Q000493:pharmacokinetics*; D011014:Pneumonia / Q000175:diagnosis / Q000378:metabolism; D012137:Respiratory System / Q000378:metabolism*; D013997:Time Factors; D014508:Urea / Q000032:analysis
chemical_list: D000900:Anti-Bacterial Agents; D007769:Lactams; D009428:Netilmicin; D014508:Urea